Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Cell Int. 2013 Mar 25;13(1):29. doi: 10.1186/1475-2867-13-29.

Mifepristone improves chemo-radiation response in glioblastoma xenografts.

Author information

  • 1Instituto Nacional de Cancerología, Subdirección de Investigación Básica, Av, San Fernando No, 22, Tlalpan 14000, Apartado Postal, 22026, México, DF, Mexico. pgarcia_lopez@yahoo.com.mx.

Abstract

BACKGROUND:

We have investigated the ability of Mifepristone, an anti-progestin and anti-glucocorticoid drug, to modulate the antitumor effect of current standard clinical treatment in glioblastoma xenografts.

METHODS:

The effect of radiation alone or combined with Mifepristone and Temozolamide was evaluated on tumor growth in glioblastoma xenografts, both in terms of preferentially triggering tumor cell death and inhibiting angiogenesis. Tumor size was measured once a week using a caliper and tumor metabolic-activity was carried out by molecular imaging using a microPET/CT scanner. The effect of Mifepristone on the expression of angiogenic factors after concomitant radio-chemotherapy was determined using a quantitative real-time PCR analysis of VEGF gene expression.

RESULTS:

The analysis of the data shows a significant antitumoral effect by the simultaneous administration of radiation-Mifepristone-Temozolamide in comparison with radiation alone or radiation-Temozolamide.

CONCLUSION:

Our results suggest that Mifepristone could improve the efficacy of chemo-radiotherapy in Glioblastoma. The addition of Mifepristone to standard radiation-Temozolamide therapy represents a potential approach as a chemo-radio-sensitizer in treating GBMs, which have very limited treatment options.

PMID:
23530939
[PubMed]
PMCID:
PMC3626552
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk